Trial Profile
Safety, tolerability and pharmacodynamic characterization of vatelizumab, a monoclonal antibody targeting very-late-antigen (VLA)-2: a randomized, double-blind, placebo-controlled phase 1 study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs Vatelizumab (Primary)
- Indications Multiple sclerosis
- Focus First in man; Pharmacodynamics; Therapeutic Use
- 19 Feb 2016 New trial record